OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN

Jiatao Li1, Dan Yang2, Yan Lin1

  • 1Institutes of Biomedical Sciences, Obstetrics & Gynecology Hospital of Fudan University, Institutes of Metabolism and Integrative Biology, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, China.

Frontiers in Pharmacology
|January 30, 2024
PubMed

Insights

The deubiquitinase OTUD3 regulates KPTN, inhibiting mTORC1 signaling and tumor cell growth. This discovery offers new insights into cancer development and potential therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Ubiquitination and deubiquitination are crucial for eukaryotic processes, with dysregulation linked to diseases like cancer.
  • The deubiquitinase OTUD3 is known to suppress tumor growth by stabilizing PTEN and inhibiting PI3K-AKT signaling.
  • However, other substrates and functions of OTUD3 remain largely unexplored.

Purpose of the Study:

  • To investigate the role of OTUD3 as a deubiquitinase for KPTN.
  • To elucidate the impact of OTUD3-KPTN interaction on the mTOR signaling pathway.
  • To explore OTUD3's influence on tumor cell proliferation and metabolic regulation.

Main Methods:

  • In vivo ubiquitination assays to assess KPTN ubiquitination by OTUD3.
  • CRISPR/Cas9 editing and immunofluorescence to study OTUD3's effect on mTOR signaling.
  • Cell proliferation assays and Nuclear Magnetic Resonance (NMR) to evaluate cellular growth impacts.

Main Results:

  • OTUD3 deubiquitinates KPTN, primarily at lysine 49, without altering KPTN protein levels, suggesting a non-degradative modification.
  • OTUD3 overexpression inhibits mTORC1 signaling, while OTUD3 knockout enhances it, independent of PTEN.
  • OTUD3 promotes GATOR1 lysosomal localization via KPTN and downregulates mTORC1, inhibiting tumor cell growth and proliferation.

Conclusions:

  • OTUD3 inhibits tumor development through KPTN-mediated regulation of the mTORC1 pathway.
  • This study reveals a novel mechanism for OTUD3 in cancer, independent of its known PTEN interaction.
  • Findings provide new insights into tumorigenesis and potential targets for cancer drug screening and therapy.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K